JP2004537289A5 - - Google Patents

Download PDF

Info

Publication number
JP2004537289A5
JP2004537289A5 JP2002588919A JP2002588919A JP2004537289A5 JP 2004537289 A5 JP2004537289 A5 JP 2004537289A5 JP 2002588919 A JP2002588919 A JP 2002588919A JP 2002588919 A JP2002588919 A JP 2002588919A JP 2004537289 A5 JP2004537289 A5 JP 2004537289A5
Authority
JP
Japan
Prior art keywords
nucleic acid
cell
hbm
antibody
lrp6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002588919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004537289A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/014877 external-priority patent/WO2002092000A2/en
Publication of JP2004537289A publication Critical patent/JP2004537289A/ja
Publication of JP2004537289A5 publication Critical patent/JP2004537289A5/ja
Withdrawn legal-status Critical Current

Links

JP2002588919A 2001-05-11 2002-05-13 骨量および脂質レベルを調整するｈｂｍ変異型 Withdrawn JP2004537289A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29007101P 2001-05-11 2001-05-11
US29131101P 2001-05-17 2001-05-17
US35305802P 2002-02-01 2002-02-01
US36129302P 2002-03-04 2002-03-04
PCT/US2002/014877 WO2002092000A2 (en) 2001-05-11 2002-05-13 Hbm variants that modulate bone mass and lipid levels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010146427A Division JP2011004744A (ja) 2001-05-11 2010-06-28 骨量および脂質レベルを調整するｈｂｍ変異型

Publications (2)

Publication Number Publication Date
JP2004537289A JP2004537289A (ja) 2004-12-16
JP2004537289A5 true JP2004537289A5 (https=) 2005-12-22

Family

ID=27501520

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002588919A Withdrawn JP2004537289A (ja) 2001-05-11 2002-05-13 骨量および脂質レベルを調整するｈｂｍ変異型
JP2002589632A Withdrawn JP2005511002A (ja) 2001-05-11 2002-05-13 骨量変調のトランスジェニック動物モデル
JP2010146427A Pending JP2011004744A (ja) 2001-05-11 2010-06-28 骨量および脂質レベルを調整するｈｂｍ変異型

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2002589632A Withdrawn JP2005511002A (ja) 2001-05-11 2002-05-13 骨量変調のトランスジェニック動物モデル
JP2010146427A Pending JP2011004744A (ja) 2001-05-11 2010-06-28 骨量および脂質レベルを調整するｈｂｍ変異型

Country Status (7)

Country Link
US (2) US7416849B2 (https=)
EP (2) EP1401269A4 (https=)
JP (3) JP2004537289A (https=)
AU (2) AU2002316095A1 (https=)
BR (2) BR0209563A (https=)
CA (2) CA2446821A1 (https=)
WO (2) WO2002092764A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780609B1 (en) * 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
US6770461B1 (en) 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
CA2410253C (en) * 2000-05-26 2010-06-15 Genome Therapeutics Corporation Regulating lipid levels via the zmax1 or hbm gene
US7514594B2 (en) * 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
JP2004537289A (ja) 2001-05-11 2004-12-16 ゲノム　セラピューティックス　コーポレーション 骨量および脂質レベルを調整するｈｂｍ変異型
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
IL158750A0 (en) * 2001-05-17 2004-05-12 Genome Therapeutics Corp Reagents and methods for modulating dkk-mediated interactions
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
CA2515081A1 (en) 2003-02-07 2004-08-19 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
FR2856410B1 (fr) * 2003-06-20 2007-06-15 Integragen Sa Methodes de preparation de puces genetiques et utilisations
WO2005048913A2 (en) * 2003-11-24 2005-06-02 Gunnar Westin Mutant lrp5/6 wnt-signaling receptors in cancer diagnosis, prognosis and treatment
CA2562833A1 (en) * 2004-04-27 2005-11-03 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
JP5236286B2 (ja) * 2004-05-07 2013-07-17 セレラ コーポレーション 肝線維症に関連する遺伝的多型、その検出方法および使用
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
US7771937B2 (en) * 2005-05-20 2010-08-10 University Of Washington Methods for predicting late onset Alzheimer disease in an individual
US20080293053A1 (en) * 2006-12-28 2008-11-27 The Regents Of The University Of Michigan shRNA Materials and Methods of Using Same for Inhibition of DKK-1
WO2009131553A2 (en) 2006-12-29 2009-10-29 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP5444553B2 (ja) 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法
KR20100091170A (ko) 2007-11-02 2010-08-18 노파르티스 아게 저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법
US8716243B2 (en) * 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
WO2009146957A1 (en) * 2008-06-03 2009-12-10 Universite De Liege Biomarker for osteoarthritis and/or other ageing-related diseases, and use thereof.
BR112012020257A8 (pt) 2010-02-11 2018-02-14 Recombinetics Inc métodos e aparelhos para produzir artiodátilos transgênicos
AR080795A1 (es) 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
KR20130066631A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
EP4234698A3 (en) 2010-05-06 2023-11-08 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
CN104039830A (zh) 2011-11-04 2014-09-10 诺华股份有限公司 低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体
CN104540382A (zh) * 2012-06-12 2015-04-22 弗·哈夫曼-拉罗切有限公司 用于产生条件性敲除等位基因的方法和组合物
US8959241B2 (en) * 2012-07-23 2015-02-17 Adobe Systems Incorporated Method and apparatus for performing server-side splicing for live streaming media
WO2015073922A2 (en) 2013-11-15 2015-05-21 Northwestern University Inhibition of oxidative stress in atrial fibrillation
EP4674963A3 (en) 2013-12-09 2026-04-29 Baylor College of Medicine Hippo and dystrophin complex signaling in cardiomyocyte renewal
TW201710503A (zh) 2015-06-12 2017-03-16 長庚醫療財團法人林口長庚紀念醫院 新穎多核苷酸、載體、醫藥組成物以及其用途
US20180037909A1 (en) 2016-08-04 2018-02-08 Chang Gung Memorial Hospital, Linkou Modified cancer cell lines and uses thereof
US20190218306A1 (en) * 2018-01-18 2019-07-18 Nalini M. Rajamannan Method of inhibiting ectopic calcification

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
WO1997012903A1 (en) 1995-10-04 1997-04-10 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
US5691153A (en) 1996-09-06 1997-11-25 Creighton University Genetic markers to detect high bone mass
US6555654B1 (en) 1997-04-15 2003-04-29 The Wellcome Trust Limited As Trustee For The Wellcome Trust LDL-receptor
WO1998046743A1 (en) * 1997-04-15 1998-10-22 The Wellcome Trust Limited As Trustee To The Wellcome Trust Novel ldl-receptor
BE1011331A6 (fr) 1997-08-20 1999-07-06 Univ Catholique De Louvain Hal Polypeptide associe au peroxysome, sequence nucleotidique encodant ledit polypeptide et leur utilisation dans le diagnostic et/ou le traitement de maladies ou de lesions pulmonaires.
EP1064289A1 (en) 1998-03-18 2001-01-03 Ariad Pharmaceuticals, Inc. Heterocyclic signal transduction inhibitors, compositions containing them
AU4023200A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 50 human secreted proteins
IL151904A0 (en) * 2000-04-05 2003-04-10 Genome Therapeutics Corp THE HIGH BONE MASS GENE OF 11q13.3
CA2410253C (en) 2000-05-26 2010-06-15 Genome Therapeutics Corporation Regulating lipid levels via the zmax1 or hbm gene
CA2411978A1 (en) * 2000-06-21 2001-12-27 Deltagen, Inc. Transgenic mice containing targeted gene disruptions
AU2001295010A1 (en) 2000-08-18 2002-03-04 Case Western Reserve University Regulator gene and system useful for the diagnosis and therapy of osteoporosis
JP2004537289A (ja) 2001-05-11 2004-12-16 ゲノム　セラピューティックス　コーポレーション 骨量および脂質レベルを調整するｈｂｍ変異型
US8637506B2 (en) 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
DE102007020878B4 (de) 2007-05-04 2020-06-18 Dr. Ing. H.C. F. Porsche Aktiengesellschaft Verfahren zur Prüfung von Umströmungsgeräuschen

Similar Documents

Publication Publication Date Title
JP2004537289A5 (https=)
Jaworski et al. Collaborative and specialized functions of Robo1 and Robo2 in spinal commissural axon guidance
Kitajiri et al. Compartmentalization established by claudin-11-based tight junctions in stria vascularis is required for hearing through generation of endocochlear potential
Strotmann et al. Olfactory receptor proteins in axonal processes of chemosensory neurons
Wang et al. Abnormalities in cartilage and bone development in the Apert syndrome FGFR2+/S252W mouse
Gwack et al. Hair loss and defective T-and B-cell function in mice lacking ORAI1
Labrador et al. The N‐terminal globular domain of Eph receptors is sufficient for ligand binding and receptor signaling
Yu et al. B cells control the migration of a subset of dendritic cells into B cell follicles via CXC chemokine ligand 13 in a lymphotoxin-dependent fashion
Han et al. Drosophila glypicans Dally and Dally-like shape the extracellular Wingless morphogen gradient in the wing disc
Lanske et al. PTH/PTHrP receptor in early development and Indian hedgehog—regulated bone growth
Knöll et al. A role for the EphA family in the topographic targeting of vomeronasal axons
Hasan et al. Incomplete block of B cell development and immunoglobulin production in mice carrying the μ MT mutation on the BALB/c background
Hisamatsu et al. Usefulness of immunoblotting using purified laminin 5 in the diagnosis of anti-laminin 5 cicatricial pemphigoid
ES2548980T3 (es) Factor de viabilidad neuronal y uso del mismo
Schweitzer et al. Paranemin and the organization of desmin filament networks
Allison et al. Genetic and environmental influences on obesity
JP2009533065A5 (https=)
Smith et al. Tissue-specific transgenic knockdown of Fos-related antigen 2 (Fra-2) expression mediated by dominant negative Fra-2
Spencer et al. Progressive Rod–Cone degeneration (PRCD) protein requires N-terminal S-acylation and rhodopsin binding for photoreceptor outer segment localization and maintaining intracellular stability
Sinkó et al. Subcellular localization and N-glycosylation of human ABCC6, expressed in MDCKII cells
Koide et al. Formation of granular cytoplasmic aggregates in COS7 cells expressing mutant Cu/Zn superoxide dismutase associated with familial amyotrophic lateral sclerosis
ES2582559T3 (es) Factor trófico para el tratamiento de las enfermedades degenerativas de la retina
Goto et al. Elimination of epiplakin by gene targeting results in acceleration of keratinocyte migration in mice
Saito et al. Induction of skin fibrosis in mice expressing a mutated fibrillin-1 gene
JP2005528080A5 (https=)